FREMONT, CA -- (Marketwired) -- 04/04/14 -- DiscoveRx Corporation, announced that the company will showcase the application of BioMAP® Primary Cell Systems, as well as the company's PathHunter® and KINOMEscan® technologies, to speed the discovery and development of new anticancer compounds at the American Association of Cancer Research Annual Meeting, being held April 5-9 in San Diego, California.
Furthermore, the company also announced the online publication in Advanced Drug Delivery Reviews (ADDR) of an article that discusses the use and value of primary human cells and co-cultures in drug discovery, illustrated by models of inflammation biology, neo-vascularization and tumor microenvironments encompassed in the BioMAP® systems assay platform.
"Assays using primary human cells and co-cultures, such as BioMAP® systems, have proven to be particularly useful in such phenotypic discovery approaches as they are more physiologically relevant to human biology than other cell-based assays while still being suitable for industrial-scale drug discovery," said Ellen Berg, Ph.D., inventor of the BioMAP platform, scientific director of DiscoveRx's BioSeek subsidiary and an author of the ADDR publication.
The new publication summarizes efforts and provides examples of primary human cell co-cultures in industrial drug discovery and screening, as well as a discussion of the challenges to the development of such assay systems. The article also describes the creation and use of specific co-culture systems developed by BioSeek related to inflammation, angiogenesis and tumor-microenvironment.
"Additional advances in cell biology, bioengineering and assay technologies, coupled with efforts to miniaturize and mass produce 3-dimensional cultures are likely to further increase the physiological relevance of industry drug discovery screening assays," commented Dr. Berg. "The ultimate result should be in vitro screening results more predictive of drug safety and efficacy, as well as compound toxicity, than is possible using any other method today."
DiscoveRx at AACR
On April 8, DiscoveRx scientists will present a poster describing the detection of EGFR, HER2, HER3 and HER4 Hetero- and Homodimerization Using Enzyme Fragment Complementation (EFC)-based PathHunter® cellular assays to monitor receptor-receptor interactions at the surface of intact cells, a method applicable to diverse receptor types such as Interleukin receptors, BMP receptors and cytokine receptors.
On April 9, DiscoveRx scientists will present a poster on the use of BioMAP® Systems and BROMOscan bromodomain ligand binding assays for the rational design of multi-targeted anticancer compounds (kinase/bromodomain inhibitors).
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, CA, San Francisco, CA and Birmingham, England. DiscoveRx is a leading provider of next generation proprietary platforms for both target-based and phenotypic based drug discovery. The company holds extensive intellectual property for its core technology platforms 1) PathHunter®, HitHunter® and InCELL Hunter: β-galactosidase based enzyme fragment complementation, 2) KINOMEscan®: in vitro binding assay platform and 3) BioMAP®: A three-part drug discovery solution consisting of the BioMAP assay systems, proprietary database of assay results on tested compounds, and predictive analytics tools. Utilizing these proprietary platforms, DiscoveRx has developed and commercialized industry leading panels of over 1000 target based and primary cell based assay solutions for Oncology, Metabolic Disease, Inflammation, CNS and Cardiovascular drug discovery research. Many of DiscoveRx's innovative solutions have been widely adopted in pharmaceutical, biotechnology and academic laboratories worldwide. For more information, visit http://www.discoverx.com